Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nogapendekin alfa inbakicept + Tri-Ad5 vaccines
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
nogapendekin alfa inbakicept + Tri-Ad5 vaccines is a combination immunotherapy developed by ImmunityBio in collaboration with the National Cancer Institute (NCI). The regimen consists of nogapendekin alfa inbakicept (also known as N-803), an IL-15 superagonist fusion protein, and Tri-Ad5, a trivalent vaccine utilizing adenovirus type 5 (Ad5) vectors to deliver three tumor-associated antigens: Carcinoembryonic Antigen (CEA), Mucin-1 (MUC1), and Brachyury. N-803 is designed to enhance the proliferation and activation of natural killer (NK) cells and CD8+ T cells by mimicking the activity of IL-15, while the Tri-Ad5 vaccine primes the immune system to recognize and attack cells expressing the targeted antigens. This combination is currently being evaluated in Phase 2 clinical trials (such as QUILT-5.015) for the prevention and treatment of colorectal cancer in patients with Lynch syndrome.
- Other names
- N-803 + Tri-Ad5NAI + Tri-Ad5nogapendekin alfa inbakicept + ETBX-011/ETBX-021/ETBX-051
02
Targets
T (Brachyury transcription factor)MUC1 (Mucin-1 Antigen)Interleukin-15 receptor subunit alpha sushi domainCEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on nogapendekin alfa inbakicept + Tri-Ad5 vaccines.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nogapendekin alfa inbakicept + Tri-Ad5 vaccines.